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Abstract
Background: Residents in care homes are often very frail, have complex medicine regimens and are at high risk of
adverse drug events. It has been recommended that one healthcare professional should assume responsibility for
their medicines management. We propose that this could be a pharmacist independent prescriber (PIP). This
feasibility study aimed to test and refine the service specification and proposed study processes to inform the
design and outcome measures of a definitive randomised controlled trial to examine the clinical and cost
effectiveness of PIPs working in care homes compared to usual care. Specific objectives included testing processes
for participant identification, recruitment and consent and assessing retention rates; determining suitability of
outcome measures and data collection processes from care homes and GP practices to inform selection of a
primary outcome measure; assessing service and research acceptability; and testing and refining the service
specification.
Methods: Mixed methods (routine data, questionnaires and focus groups/interviews) were used in this non-
randomised open feasibility study of a 3-month PIP intervention in care homes for older people. Data were
collected at baseline and 3months. One PIP, trained in service delivery, one GP practice and up to three care
homes were recruited at each of four UK locations. For ten eligible residents (≥ 65 years, on at least one regular
medication) in each home, the PIP undertook management of medicines, repeat prescription authorisation, referral
to other healthcare professionals and staff training. Outcomes (falls, medications, resident’s quality of life and
activities of daily living, mental state and adverse events) were described at baseline and follow-up and assessed for
inclusion in the main study. Participants’ views post-intervention were captured in audio-recorded focus groups and
semi-structured interviews. Transcripts were thematically analysed.
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Results: Across the four locations, 44 GP practices and 16 PIPs expressed interest in taking part; all care homes
invited agreed to take part. Two thirds of residents approached consented to participate (53/86). Forty residents
were recruited (mean age 84 years; 61% (24) were female), and 38 participants remained at 3 months (two died). All
GP practices, PIPs and care homes were retained. The number of falls per participating resident was selected as the
primary outcome, following assessment of the different outcome measures against predetermined criteria. The
chosen secondary outcomes/outcome measures include total falls, drug burden index (DBI), hospitalisations,
mortality, activities of daily living (Barthel (proxy)) and quality of life (ED-5Q-5 L (face-to-face and proxy)) and
selected items from the STOPP/START guidance that could be assessed without need for clinical judgement. No
adverse drug events were reported. The PIP service was generally well received by the majority of stakeholders
(care home staff, GPS, residents, relatives and other health care professionals). PIPs reported feeling more confident
implementing change following the training but reported challenges accommodating the new service within their
existing workload.
Conclusion: Implementing a PIP service in care homes is feasible and acceptable to care home residents, staff and
clinicians. Findings have informed refinements to the service specification, PIP training, recruitment to the future
RCT and the choice of outcomes and outcome measures. The full RCT with internal pilot started in February 2016
and results are expected to be available in mid late 2020.
Introduction
Background
Globally, the population is increasing and ageing. Be-
tween 2015 and 2050, the proportion of the world’s
population over 60 years will nearly double from 12% to
22% [1]. These changes put pressure on health systems,
increasing the need for care. Old age is associated with
increasing dependency and vulnerability, declining in-
come and poorer health, and many people require resi-
dential care. Whilst globally, the number of beds in
nursing and care homes have increased [2]. In the UK,
capacity has remained almost static since 2005 [3].
Care home residents are often frail, have multiple mor-
bidities and need high levels of support. Most are pre-
scribed a large number of medicines, rendering them
particularly vulnerable to adverse drug reactions and er-
rors [4]. The UK-based Care Homes’ Use of Medicines
Study (CHUMS) found several areas of concerns around
medicine management in care homes including errors
with medication, prescribing, biochemical monitoring and
administration [5, 6]. These findings were corroborated in
a systematic review which considered interventions to op-
timise prescribing for older people in care homes [7].
The CHUMS study proposed that one person should
adopt overall continuing responsibility for medicines
management, working with a lead general practitioner
(GP) within each care home. The UK Department of
Health Immediate Action Alert [8] arising from CHUMS
required primary care organisations, GPs and pharmacy
contractors to establish effective joint working strategies
to address the identified concerns. However, a recent
Cochrane Review [7] suggests that despite the recom-
mendations in the Immediate Action Alert, care remains
sub-optimal and more effective frequent medicines
management interventions in this setting are required.
The Care Quality Commission identified the proper and
safe use of medicines as one area of care that requires
regular review and which continues to fall below the ex-
pected standards [9].
Recent changes in UK legislation, enabling suitably
trained pharmacists to prescribe [10], have provided an
opportunity for pharmacist independent prescribers
(PIPs) to assume the central prescribing-related role in
the care home environment proposed by CHUMS. This
role could also incorporate medication review and im-
plementation of any identified changes, management of
care home repeat prescribing, medicine reconciliation
(when care home patients are discharged back from hos-
pital) and support for care home staff in drug ordering
and stock control.
Evidence from the UK [11] suggests that practice-
based PIPs can prescribe safely and improve patient out-
comes for patients with chronic pain compared to both
medication review followed by recommendation to the
GP and usual GP-led care without any pharmacist re-
view. A similar service model, in which a PIP assumes
responsibility for overall management of an individual
care home resident’s medicines, monitoring and author-
ising repeat prescriptions based on individualised
pharmaceutical care plans (PCPs), could also improve
patient outcomes. The PCPs, as a detailed record of all
resident-related medication activities, could be used to
communicate prescribing decisions and plans to the care
home staff, residents, GP and any other relevant mem-
bers of the care team.
Despite some successful service-development projects
based on this model [12], there is no randomised con-
trolled trial evidence that, in a care home setting, a PIP
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can improve the clinical outcomes for residents com-
pared to usual care. The feasibility study reported in this
paper is part of a programme of work (https://www.uea.
ac.uk/chipps/) which follows the Medical Research
Council (MRC) guidelines on developing and evaluating
a complex intervention [13]. The ultimate aim is to con-
duct a definitive randomised controlled trial (RCT) to
compare the effectiveness and cost effectiveness of a
pharmacist independent prescriber managing care home
residents’ medication compared to usual GP-led care.
Earlier parts of the programme have defined the pro-
posed service and identified logistical and professional
barriers and solutions to address them [14] and have de-
vised a training programme for the PIPs to ensure they
have the requisite competencies to deliver the service
and identified provisional measures of outcome [15].
Aims and objectives
The aim of this feasibility study was to test and refine
the service specification and proposed study processes in
order to inform the subsequent definitive cluster rando-
mised controlled trial.
Specific objectives
The specific objectives were to do the following:
 Test processes for participant identification
(pharmacist independent prescribers, GP practices,
care homes and care home residents), recruitment
and consent, and assess retention rates.
 Determine suitability of outcome measures and data
collection processes from care homes and GP practices.
 Assess service and research acceptability to care
home residents, pharmacist independent prescribers,
GPs and care home staff
 Test and refine the service specification
Method
Trial design
This was a single-arm, open feasibility study conducted
in care homes for older people. The study was con-
ducted in four locations across the UK, Grampian
(Scotland), Belfast (Northern Ireland), Norfolk (Eng-
land), and Yorkshire (England).
Each location was asked to recruit one eligible general
practice, one pharmacist independent prescriber (PIP)
and up to three care homes associated with each partici-
pating practice. Each GP/PIP/care home triad had a tar-
get of recruiting 10 residents.
Inclusion criteria for participants
GP practice
GP practice managing sufficient care home residents to
recruit a minimum of 10 residents in up to three care
homes. An existing arrangement with a PIP (see below)
was preferred.
PIPs
Pharmacists registered with the General Pharmaceutical
Council/Pharmaceutical Society of Northern Ireland as a
pharmacist independent prescriber and following train-
ing, provided by the CHIPPS team, demonstrating com-
petence in the service delivery of the proposed
intervention
Care homes
Care home primarily caring for residents aged 65 years
and over, registered with the Care Quality Commission
(CQC) (England), Care Inspectorate (Scotland) or Regu-
lation and Quality Improvement Authority (RQIA)
(Northern Ireland) as caring for adults aged 65 years and
over. Residential, nursing homes and those with both
categories of resident were eligible.
Residents
Residents under the care of the participating GP prac-
tice, prescribed at least one regular medication, aged 65
years and over and permanent resident in the care
home, who were able to provide informed consent/
assent, or for this to be provided by a nominated repre-
sentative. Residents were excluded if they were on an
end of life care pathway or receiving their care primarily
from secondary care.
Participant identification and recruitment
PIPs and GP practices
Between August and September 2016 each location used
locally defined strategies (see Additional file 1) and ap-
propriate local networks to obtain expressions of interest
(EOI) from GP practices and PIPs, for either participat-
ing in the feasibility study or the planned main RCT.
Based on earlier qualitative findings [14], final selection
prioritised practices that had an established working re-
lationship with a PIP. Details of recruitment are shown
in Table 1 below and each location was advised to use
locally supported approaches (see Additional file 1).
Care homes
The consenting GP practice in each study location in-
vited up to three care homes (see inclusion criteria)
served by their practice to note their interest in participat-
ing in the study. The care home managers expressing an
interest were sent a formal invitation pack by the local re-
searchers (including letter and information sheet). A sec-
ond or third care home was only contacted if there were
insufficient residents in one home.
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Residents
Between November 2016 and January 2017, GPs identi-
fied eligible care home residents in their care from their
computerised lists. An invitation pack (letter from the
GP, participant information sheet (spoken version if ne-
cessary)) was distributed to each resident via the care
home manager. After a minimum of 24 h, the care home
manager visited each resident and obtained verbal con-
sent from residents willing to discuss the study further
with the study researcher. The local research associate
(RA) visited the care home, met with interested resi-
dents, assessed their capacity to give consent and took
formal signed consent. Where a resident was identified
by the care home manager or RA as lacking capacity, a
legally appropriate third party (e.g. relative/friend known
as consultee (England and Northern Ireland) or welfare
power of attorney (WPOA; Scotland)), was contacted by
mailed invitation pack. A reminder letter was issued
after 2 weeks, if no response had been received. In Eng-
land and Northern Ireland, if there was no reply from
the potential consultee, a consultee from within the care
home staff was nominated to provide consent. In
Scotland, this is not an approved approach and if there
was no reply from the designated WPOA, the resident
could not be recruited (see Fig. 1).
GPs were paid for their contribution to patient identi-
fication and recruitment and for taking part in the inter-
views, in line with national guidance (https://www.gov.
uk/government/publications/guidance-on-attributing-
the-costs-of-health-and-social-care-research).
Sample size
Since this feasibility study was not designed to assess ef-
ficacy, no formal power calculation was conducted. The
recruitment target was 10 participants per site (40 in
total), in line with recommended practice as judged suf-
ficient to assess feasibility [16].
The intervention
The PIP intervention focused on four key areas in-
cluding medication review, prescribing, training and
support, and communication. The detailed service
specification which was developed in earlier parts of
the programme is attached in Additional file 2. A
summary of the proposed service is shown in Fig. 2
below. The main tasks were reviewing a resident’s
medication, developing and implementing a pharma-
ceutical care plan, prescribing and deprescribing, re-
ferral to other health care professionals as agreed
with GP, improving communication between GP prac-
tice and care home and local community pharmacy,
and supporting systematic ordering, prescribing, and
administration processes and training for care home
and GP staff. As members of the GP team, PIPs all
had access to GP records.
The intervention ran for a period of 90 days from Feb-
ruary to April 2017. There was an indicative time alloca-
tion of 4 h per week per PIP per 10 residents. Pre-
intervention, PIPs attended 2 days training (January
2017) which included an overview of the trial design,
project delivery, and preparation for the role; the service
specification and usage of the PCPs were discussed in
depth. This was followed by time to develop relation-
ships with medical practices (for those naive to the prac-
tice), care homes and community pharmacists, including
performing medication reviews with GPs and observing
medication administration by care staff, before final
sign-off by clinically qualified professionals independent
of the research team. The programme of work which
underpinned the development of the training will be re-
ported in full in a separate publication. PCPs were used
by the PIP to document each intervention and to com-
municate any medicines management issues to key
stakeholders. A random sample of eight PCPs (two per
location) was selected using a random number generator
and these were reviewed for appropriateness by one of
two grant holders who were specialists in care of the
elderly medicine. Assessment was based on professional
judgement.
Estimating the participating proportion of the eligible
population
Participants included PIPs, GP practices, care homes
and residents. The proportion of pharmacists, general
practices, care homes and residents approached who
consented to participate was recorded along with the
proportion of residents followed-up at 3 months to as-
sess recruitment and retention.
Table 1 Baseline and follow-up recruitment and retention
Total number invited Total number of EOIs (%) Number participating at baseline Number participating at follow-up (%)
GP Practices 346 44 (11.6) 4 4 (100)
*PIPs 14 6 (42.8) 4 4 (100)
**Care Homes 6 n/a 6 6 (100)
Residents 86 53 (62.2) 40 40 (100) (2 died)
*Numbers based on two areas. In two areas, PIPs were approached sequentially until one agreed
**One care home in each of three areas and three care homes in one area
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Suitability of outcomes and outcome measures
Potential outcomes and outcome measures were identi-
fied in earlier parts of the programme [15] (see Table 2).
All were collected by local researchers at baseline and 3-
month follow-up for each participant from records held
in the care home, or GP practice, and face to face com-
pletion of standard outcome tools with residents and
care home staff. To determine their number of
Fig. 1 Care home resident recruitment flow chart
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medicines suitability for inclusion in the RCT, each of the
outcomes/outcome measures was assessed against the fol-
lowing criteria: availability of the data source, potential for
bias, potential for missing data, resident centeredness,
sensitivity to the intervention (i.e. an indication of
change), reliability of data, whether tool was validated, po-
tential for third party completion, ability to blind, time
taken to collect per patient and completeness of data. To
inform the final selection, performance against these cri-
teria was combined with information on the outcome
measure from the literature and general guidance [15].
The minimum criteria for an outcome to be retained in a
subsequent RCT were that it should be objective, discrim-
inating, and efficient to collect.
Assessment of the service and research acceptability and
feasibility
Participant views
To assess participant views post-intervention, a mini-
mum of one member of care home staff, the care home
manager, two residents/relatives and the responsible GP
at each location were invited to take part in a face-to-
face semi-structured interview. A cross-centre focus
group was undertaken with the PIPs, led by study RAs,
following a topic guide which included views on the ac-
ceptability of the service, and its implementation as well
as perceptions of the working relationship with the PIP.
All proceedings were digitally recorded and transcribed
verbatim.
Serious adverse events (ADE)
All admissions to hospital and deaths were recorded as
serious adverse events (SAEs) and assessed for causality
by a medical doctor on the study management team,
using professional judgement.
Data analysis
Descriptive statistics were used to describe the quantita-
tive outcome measures for baseline and follow-up where
appropriate. No statistical comparisons were conducted.
Interview and focus group transcripts were thematically
analysed using a combined deductive-inductive approach.
Results
Recruitment and retention
Details of recruitment are shown in Table 1 and Fig. 3
below and varied based on local preferences (see Add-
itional file 1). In one site, invitations were sent to a ran-
dom sample (100) of all GP practices in their area; in
another site, all practices known to be research active
were invited (50); whilst in another site, invitations were
sent to GP practices known to provide a service to care
homes [20]; and in the final site all practices in five clin-
ical commissioning groups (171) were invited and then
the PIP approached those expressing interest. Over 11%
of GPs invited (11.6% (44/346)) and over 40% of PIPs
Fig. 2 Summary of PIP service
Table 2 Outcomes/outcome measures used in the feasibility
study
• STOPP/START (medication appropriateness tool) [17]
• Drug burden index [18]
• Fall rate per patient as per standard care home safety data collection
• Adverse drug events as would normally be reported by a care home
• Mortality
• Barthel Index (physical functioning) [19]
• Mini Mental State Examination (MMSE) (Cognitive functioning) [20]
• Qualidem [21] (dementia specific quality of life)
• EuroQoL EQ-5D-5 L [2] (Proxy version 1). The proxy (care home staff,
key worker) was asked to rate how he or she (i.e. the proxy), would
rate the subject’s health (quality of life) [22]
• EuroQol EQ-5D-5 L face-to-face with resident (quality of life) [22]
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(42.8% (6/14)) expressed an interest in taking part in ei-
ther this feasibility study or the subsequent randomised
trial. In two areas, potentially eligible PIPs were
approached sequentially and the first one agreeing was
recruited (see Table 1 and Additional file 1). In the other
two areas, a larger number of potentially eligible PIPs
were identified and all were invited to take part. The re-
sponse rate for the PIPs is based on these latter two
areas only. All invited care homes agreed to be part of
the study. The four recruited PIPs were either employed
directly by the practice [1], by the NHS [2] or self-
employed [1]. One of the NHS-employed PIPs did not
have an existing relationship with the GP.
The GP or PIP assessed 122 residents, identified from
GP records, against the study inclusion criteria and ex-
cluded 36 (30%). Eighty-six residents were invited to
take part, of whom 53 (62%) agreed. In total, 27 (31%)
did not reply and six (7%) declined. Of the 53 who
agreed, 40 were recruited; the remaining 13 were placed
on a reserve list. Over half were female, (24, (60%)),
mean age was 84 years (range 67–96 years), and 32
(80%) required nursing care.
In the three-month intervention period, two (5%) resi-
dents died. All other residents were retained.
Suitability of outcome measures
There was data for all standard outcomes (see Table 3)
for all or most residents, other than their mental cap-
acity as assessed by the MMSE which could only be
completed by 40% and 35% of residents respectively at
baseline and follow-up. The direction of change between
baseline and follow-up for most outcome measures sug-
gested improvement. The fall rate, the mean Barthel
Index, the mean DBI, the number of prescribed medi-
cines and the number of medicines changes as a result
of applying the STOPP/START criteria all showed a re-
duction (i.e. improvement), and the mean MMSE and
two Qualidem domain scores (‘care relationship’ and
‘feeling at home’) increased (improved) at follow-up.
Whilst the proxy ED-5Q-5 L visual analogue scale (VAS)
Fig. 3 CHIPPS WP5 feasibility study CONSORT Diagram, 20 June 2017
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Table 3 Data generated by proposed outcome measures at baseline and follow-up
Measure Baseline Follow-up
STOPP mean (per patient) (range) SD#
Median (IQR)
3.27 (0–7) 1.96
3.0 (2.0–4.25)
2.54 (0–5) 1.24,
2.0 (2.0–3.25)
START mean (per patient) (range) SD#
Median (IQR)
2.35 (0–6)1.42
2 (1–3)
2.05 (0–6) 1.55
2.0 (1.0–3.0)
*Falls in past 3 months (total number) 12 10
Falls in past 3 months (number of patients falling) 9/40 (20%) 7/40 (17.5%)
Falls per person (mean (range) SD)
Median (IQR)
0.33 (0–3) 0.694
0.0 (0–0)
0.25 (0–2) 0.588
0.0 (0–0)
Barthel mean (range) SD
Median (IQR)
6.53 (0–17) 5.50
6.5 (1–9)
6.38 (0–19) 5.51
6.0 (1.0–10.0)
***MMSE mean (range) SD
Median (IQR)
Number
20.13 (9–30) 7.03
21.0 (14.25–25.5)
(n = 16)
20.79 (11–29) 5.90
20.5 (15–26)
(n = 14)
Drug burden index (DBI) score 0 (n (%)) 14 (35%) 14 (35%)
**Drug burden index (DBI) N score > 0 (n (%))
Mean (range) SD
Median (IQR)
26 (65%)
1.11 (0.14–3.37) 0.74
1.035 (0.5–1.5)
26 (65%)
0.93 (0.14–3.34) 0.67
0.76 (0.5–1.17
Number of medicines per patient mean (range) SD)
Median (IQR) (includes topical preparations)
9.3 (1–26) 5.9
8.5 (6–12)
8.7 (0–31) 6.0
8 (5–10)
Total Qualidem mean, (range) SD,
Median, (IQR)
93 (67–130) 15.55
91.0 (79.25–101.5)
77.85 (31–109) 18.32
79.0 (71.0–92.5)
a. Care relationship (mean (range) SD,
Median (IQR)
15.33 (10–23) 3.53
14.0 (12.25–18.0)
15.83 (4–21) 5.00
16.0 (13.0–20.0)
b. Positive Affect mean (range) SD
Median (IQR)
14.33 (6–24) 5.50
14.5 (9.0–18.75)
12.43 (2–18) 4.33
14.0 (8.5–16.0)
c. Negative Affect mean (range) SD
Median (IQR)
8.25 (3–12) 2.25
9.0 (6.0–10.0)
5.35 (0–9) 2.28
5.0 (4.0–7.0)
d. Restless/tense behaviour mean (range) SD
Median (IQR)
8.48 (3–12) 2.59
9.0 (6.25–10.0)
5.13 (0–9) 2.41
5.0 (4.0–7.0)
e. Positive self-image mean (range) SD
Median (IQR)
7.88 (3–11) 1.88
8.0 (6.0–9.0)
6.23 (0–9) 2.24
6.0 (4.25–8.75)
f. Social Relations mean (range) SD
Median (IQR)
12.03 (7–22) 3.68
11.0 (10.0–13.0)
11.13 (1–18) 4.79
10.5 (8.25–15.75)
g. Social Isolation (mean (range) SD
Median (IQR)
6.00 (3–11) 1.45
6.0 (5.0–7.0)
4.60 (10–9) 1.99
5.0 (4.0–6.0)
h. Feeling at home mean (range) SD
Median (IQR)
8.88 (6–14) 2.22
8.0 (7.0–11.0)
9.68 (1–12) 2.74
11.0 (8.0–12.0)
†EQ 5D-5 L (self)
(Mean (range) SD) median (IQR)
N
0.449 (−0.281–0.951) 0.335
0.379 (0.279–0.719)
n = 16
0.572 (0.027–1.000) 0.327
0.585 (0.34–0.77)
n = 13
†EQ 5D-5 L (proxy) (mean (range) SD)
Median (IQR)
N
0.434 (−0.027–0.896) 0.229
0.356 (0.267–0.664)
n = 39
0.406 (−0.019–0.887) 0.236
0.341 (0.206–0.581)
n = 38
†EQ 5D-5 L Baseline VAS (self) (mean (range) SD)
Median (IQR)
N
57.5 (0–100) 31.9
67.5 (32.5–75)
n = 14
62.9 (10–99) 30.2
75 (30–85)
n = 11
†EQ 5D-5 L Baseline VAS (proxy) (mean (range) SD)
Median (IQR)
N
51.6 (2–99) 23.9
57.5 (38.75–66.25)
n = 38
50.2 (2–90) 27.3
50 (30–70)
n = 37
Adverse drug events related to intervention (ADEs)
in past three months
0/40 (0%) 0/40 (0%)
#Number of individual medicines which would need to be altered (stopped or started) after researchers with a pharmacy qualification applied STOPPSTART
criteria. *NICE (2017) https://www.nice.org.uk/guidance/qs86/resources/falls-in-older-people-pdf-2098911933637, defines a fall as an unintentional or
unexpected loss of balance resulting in coming to rest on the floor, the ground or an object below knee level. **Calculation based only on those with any DBI
score. †ED5D-5 L index obtained from Devlin et al. [22] on https://euroqol.org, accessed June 2017. ***Average MMSE for the 12 participants who completed
the MMSE face to face at both base line and follow-up was 20.5 and 22.1, respectively
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decreased slightly (i.e. worsened), the self-completed VAS
increased (improved). Total Qualidem and six Qualidem
domain scores (positive affect, negative affect, restless
tense behaviour, positive self-image, social relations and
social isolation) all reduced (i.e. deteriorated) in value.
Performance of each outcome against the predeter-
mined criteria was combined with data from the litera-
ture and discussed by the Programme Management
Group. The outcome measure fulfilling most of the cri-
teria was falls per patient, and it was selected as the pri-
mary outcome measure for the definitive trial. DBI,
hospitalisations, mortality, Barthel (proxy) and ED-5Q-5
L (face-to-face and proxy) and selected items from the
STOPP/START guidance also performed reasonably well
and were retained as secondary outcomes. Some items
from STOPP START were identified as needing clinical
judgement and detailed knowledge of the patient’s med-
ical history and these were not recommended for reten-
tion. Other measures such as the Qualidem and MMSE
were dropped as time-consuming to complete, a better
measure was available (to replace the Qualidem), or
there was a high potential for bias and missing data/not
completed (applied to MMSE) (Additional file 3).
Adverse events/serious adverse event
Just over 10% of residents (5/40 (12.5%) were admitted
to hospital (11 hospital admissions in total, including
one resident admitted seven times), and two further resi-
dents died (5%). None of the hospital admissions or
deaths were judged as being related to the intervention.
Quality of pharmaceutical care plans
Eight PCPs were reviewed by two doctors. They agreed
with all actions documented in six PCPs: two of the care
plans were not fully completed and the doctors com-
mented that it was difficult to comment on the changes
without the full resident picture.
Participant views of service and research acceptability
Twenty-eight interviews were conducted across the four
sites. Six interviews were completed with each of the care
home managers and GPs. Ten interviews were conducted
with care home staff, two with residents, three with rela-
tives and one with a dietician. None of those invited de-
clined to take part, although due to lack of capacity the
number of residents interviewed was less than the target.
All participants expressed positive views about their
experience of the new service. The main themes emer-
ging from analysis were improved patient care, improved
patient safety and saving staff time and effort. These are
summarised below and illustrated with exemplar quotes
identified in italics. Participants are identified only by
their professional group due to the small numbers and
need to preserve anonymity.
Improved patient care
Regular medicine review was reported to lead to im-
proved patient care and quality of life and partici-
pants identified utilising the PIPs’ knowledge base
and skill set to strengthen the primary care team as
beneficial, particularly in vulnerable patients with
medically complex multiple morbidities. The key
pharmacist skills seen as positively impacting on care
provided to residents by supporting, care home staff
and GPs were pharmacy knowledge, their ability to
prescribe, professionalism, autonomy, ability to pro-
vide training and communication. This was sum-
marised by a care home manager: The following
quotes from a GP and Care Home Manager illustrate
the above summary.
I think you know overall it just had led to better
patient care, better medicines management you know
for those patients and nursing homes. (GP)
She’s very professional in the fact that you know that
she knows what she’s talking about so there’s no
question about it. (CH manager)
Improved patient safety
Care home managers highlighted the value of the
professional support of a pharmacist which had
made practice safer including practical aspects of
optimising administration routes which required
pharmaceutical knowledge. This is illustrated by the
following quote:
Swallowing issues, what medicines are suitable for
crushing, different formulations … … .. having the
pharmacist part of the care home makes it safer again
for that reason because GPs will just automatically say
oh well crush because we can’t afford to give you
liquid. (CH manager)
Saving staff time and effort—more efficient
There were several examples where having the PIP
on site increased efficiency within the care home
and GP practices. In the care home, it was per-
ceived that the PIP was able to have a significant
impact on speed of implementation of changes to
medication and prescriptions for acute ailments
since the PIP had direct access to GP practice com-
puter systems and therefore did not have the same
barriers to overcome as care home staff. Care home
managers also reported PIPs saved them time as
they did not need to verify dosages of medicines,
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and a dementia nurse highlighted that having a
pharmacist who could prescribe was particularly
helpful to them. These points are illustrated by the
following quotes:
Sometimes I find when you go through GPs it takes
much longer if, you know, if you ask them to reduce
something, … .then they pass it on. I found with XXX
(PIP) after her phone call, it’s implemented straight
away, you know, there’s no hanging around, which is
good, I like that. (CH manager)
I also know there’s a professional behind me that’s
doing something that I don’t have to double check at
all. (CH manager)
Well I really welcomed it because I think all the care
homes could do with an independent practitioner …
… having to wait 48 hours for an urgent prescription
and it’s just been horrendous before you came in
regards to trying to get what we need from the
surgery so having XXX (PIP) here was wonderful.
(Nurse)
In addition, the benefits of the PIP having time to
communicate with relatives and care home staff were
noted and care home managers expressed the view that
the PIP had more time than GPs to complete detailed
medication reviews for residents:
I think the pharmacist was able to spend more time
with us and the resident looking at the medications
that they were on, speaking to the staff who knew the
residents really well and getting a detailed history
which unfortunately we know the GPs haven’t got the
time to do that so we thought it was really... … really
helpful, yeah. (CH manager)
Time was also freed up for GPs, in particular in
reviewing a resident’s medication and being able to work
autonomously as a prescriber.
It was very good. XXX (PIP) did most of the
work. I had some involvement with looking at the
plans and reviewing them and also kind of any
bits of advice, but she did most of the work
herself and led it herself so I wasn’t hugely
involved. (GP)
Care home managers commented that the PIP service
did not impact on the day-to-day workload in running
the care home and although the PIP needed to discuss
resident’s PCPs with the GP, this time was absorbed
within the staff workload:
It didn’t really impede on the day to day running of
the home, it wasn’t really intrusive to the residents’
day to day lives. (CH deputy manager)
There was some increased workload for the staff
because of the time that we needed to give to the
pharmacist to discuss the resident in more detail and
sort of you know providing the relevant care plans …
.. but generally any changes were done at the
beginning of the monthly cycle so there wasn’t that
much extra work involved. (CH manager)
Finally, it was suggested that the PIP reduced stress
levels and improved communication:
Absolutely, if we could have a XXX (PIP) in every single
practice, and I know that’s hopefully what’s gonna
happen, it would make my job so much easier … . I can
see it could make my job a lot less stressful if we had
that service right across the board. (CH manager)
Potential disadvantages of the service
The main potential disadvantage suggested by care home
staff was that the PIP would not be as familiar with the
patients as the GP, and GPs expressed concern that they
would become less familiar with the residents and the
care home staff if they were less involved, as articulated
by one GP:
With the lady in question she was saying but the
pharmacist doesn’t know her, the pharmacist doesn’t
know her history. (CH manager)
because XXX (PIP) is going in and dealing with maybe
some of the issues that we would have dealt with in the
past, that there’s the potential that you see your patients
less and you have less of a close relationship with some
patients in the nursing homes so that would be a
potential negative going forward … . … … , we may
have less contact, but I don’t think there would be any
major negative impact from such a scheme. (GP)
Refinements to service specification
Two of the four PIP pharmacists attended the focus
group. Two were unwell on the day and could not at-
tend but were followed-up by individual telephone inter-
view. One interview was recorded and transcribed and
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the other recorded by notes only due to a failure of the
recording equipment. The output from the focus groups
and interviews was combined for the analysis.
The PIPs proposed a few minor changes to the service
specification. They reported using the service specifica-
tion to describe the study and discuss the PIP remit in
the care home with GPs. They suggested ‘clarification of
directions’ for medicines was ‘essential’ and that consul-
tations should be conducted face-to face ‘where possible’,
to allow for those relatives who did not live near their
relative’s care home. They also commented that deliver-
ing the service took more time than had been indicated
and suggested some minor simplification to the PCP
documentation. The following quote from one PIP, who
did not have an existing relationship with the GP prac-
tice, suggests that this may lead to challenges in finding
time to work together due to other commitments.
… . the engagement from Doctor … .. as the sort of
the overall lead GP for that care home, was very
disappointing. Initially it started off a little bit more
positive in that I did get to shadow him and spend a
bit of time with him, but again due to my other roles
with the CCG (Clinical Commissioning Group) and
also due to his sort of time commitments, we just
didn’t seem to be able to catch opportunities to meet
and liaise with each other as we ideally should’ve been
able to do. (PIP)
Discussion
Summary of findings
The findings from this non-randomised study support
the feasibility and acceptability of proceeding to the
main trial. The processes successfully identified and re-
cruited trial participants (GPs, PIPs, care homes, and
residents) and retained them in the study for 3 months.
In particular, no problems were identified with the
approach to recruiting participants without capacity, in-
cluding use of consultees and welfare power of attorneys.
A range of outcomes/outcome measures was tested and
a subset verified as suitable for efficient collection with
larger participant numbers. The new service, in which a
PIP was introduced into the care home environment
was welcomed by all stakeholders. Areas of the service
specification that could be changed to enhance the ser-
vice were identified, but nothing substantive required
change.
Strengths
The success of this non-randomised feasibility study, re-
ported in line with relevant checklist items from recent
guidance on randomised pilot studies (CONSORT [23]),
reflects the thorough iterative development process. This
ensured that the service was tested and the model devel-
oped in a way that was acceptable and met stakeholder
needs. The feasibility study has allowed the development
of detailed Gantt charts detailing timing of recruitment
of PIPs, GPs, care homes and residents, randomisation
and training of PIPs to fulfil the full programme of work
for the definitive RCT. Blinding of RAs at each site when
recruiting has also been incorporated into the manage-
ment of the project to minimise recruitment bias. Selec-
tion of the primary outcome/outcome measure for the
main trial was based on predetermined evidence-based
criteria, using data collected during this feasibility study
and from the literature. This removed any bias that
might have been introduced by a post hoc subjective
process. Finally, our stepwise process to assessing cap-
acity of care home residents to consent ensured all who
were able gave informed consent. The process was de-
veloped by the team and complies with the implied rec-
ommendations for good practice suggested in the
literature by DiazOrdaz et al. [24].
Limitations
Whilst feasibility of the service is confirmed and out-
come measures agreed, the challenges of blinding and
the willingness of participants to be recruited to a ran-
domised study was not explored within this feasibility
study. These uncertainties will be addressed by the in-
ternal pilot phase of the definitive RCT. This internal
pilot also has defined progression criteria.
A further limitation is a risk of bias. Whilst most out-
comes were objective, there was bias when a study team
member used professional judgement to assess whether
there was a potential causal association between the re-
ported adverse event(s) and the intervention. In the
main study, independent GPs will be employed to under-
take this assessment following a standard protocol. Simi-
larly, review of the PCPs, conducted by study team
members and based on professional judgement, could
have been biassed. In the main trial, this process has
been standardised with a detailed protocol and reporting
templates. The main trial will be advised by continued
advice from the independent Programme Steering Com-
mittee and a newly convened Data Monitoring and Eth-
ics Committee, and any further changes they suggest to
reduce bias will be implemented.
Generalisability
The findings from four sites, in three devolved nations,
demonstrate that the service is feasible in an increasingly
divergent UK NHS system. The participant demograph-
ics (age, sex, number of prescribed medicines, problems
identified) were similar to those of the UK care home
population [6], and participation rates were good, sug-
gesting there had not been selective recruitment. The
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PIPs participating in this study included pharmacists
employed by either primary care or the GP practice pro-
viding evidence that this service specification is adapt-
able to either model, although PIPs with a pre-existing
relationship with the GP found it easier to arrange meet-
ings. All methods for participant identification, recruit-
ment and follow-up were implemented without any
problems being identified and are all scalable. The main
trial will use cluster-randomisation by triad (GP, PIP,
care home) to avoid contamination. The acceptability of
this design to participants remains unknown.
Feasibility of recruitment process/estimation of the
eligible population
Recruitment was smooth at all levels, especially where a
more targeted approach to GPs known to work with
both a care home and with a PIP in post was adopted.
Arrangements for gaining third party consent went
smoothly, and these were (post hoc) recognised as fol-
lowing published recommendations [24]. Study retention
was good with no GP practices, care homes, PIPs or res-
idents lost to follow-up. The level of expressions of
interest from eligible GPs confirmed sufficient partici-
pants for the main trial and the consent rate of residents
has informed the target number of care home patients
required to be registered with the participating GP.
Suitability of outcomes
Following assessment of the outcomes for applicability
against the predetermined criteria, falls per patient in
the past 6 months was chosen as the primary outcome.
Falls have a theoretically informed causal link with the
intervention [25], are applicable to a clinically heteroge-
neous population and are resident centred. The potential
for missing data is minimised as the national inspection
services (Care Quality Commission/Care Inspectorate/
Regulation and Quality Improvement Authority) have
mandated and standardised procedures in place for
recording falls. Other studies have reported significant
reductions in falls of approximately 40% following
pharmacist medication reviews [25–27]. The chosen sec-
ondary outcomes/outcome measures include total falls,
DBI, hospitalisations, mortality, Barthel (proxy) and ED-
5Q-5 L (face-to-face and proxy) and selected items from
the STOPP/START guidance.
Following accepted guidance [28], all hospitalisations
are considered serious adverse events; however, in a
population of care home residents, they are relatively
frequent and in the feasibility study, their reporting rep-
resented a heavy workload, yet none of the events was
judged to be associated with the intervention. In the
main study, a two-stage SAE reporting procedure will be
incorporated into a Safety Management Plan, with only
those events with a plausible link to the intervention, as
judged by the triad GP, to be reported to the Clinical
Trials Unit within 24 h. Further, a proportion of deaths
and hospitalisation will be reviewed by an independent
GP to ensure unbiased decision-making in assessing
whether adverse events are likely to be related to the
trial intervention.
In the feasibility study, no other ADEs were reported;
therefore, ADEs were discounted as an outcome meas-
ure. However, since ADEs are highly significant to pa-
tient safety, their reporting will be retained in the RCT
as part of the assessment of safety, with systems in place
to allow anyone involved in the study to report these.
Implications for refining the service specification
Care home managers and staff, and GPs all welcomed the
intervention and identified benefits of the PIP service.
Having the support of an accessible qualified professional
who was able to act independently was seen by both GPs
and care home staff as improving the quality of care and
making processes more efficient. None offered any sugges-
tions for change. The level of detail recorded on the PCP
varied between PIPs which highlighted the need for a
more consistent approach to completing the PCP which
would be addressed during the training of the PIPS prior
to the start of the main trial. The PIPs reported that com-
pleting the PCP was time-consuming and suggested some
changes to ensure the required data could be recorded ef-
ficiently whilst avoiding duplication.
Conclusion
This study has confirmed the acceptability and feasibility
of the processes for participant identification, recruit-
ment and informed consent. The PIP service was
deemed acceptable to all stakeholders and detailed the
particular benefits perceived by GPs and care home staff.
Appropriate outcome measures and tools for use in the
definitive RCT have been identified, and testing has in-
formed minor refinements to the service specification
and protocol for the final phase of this programme of
research. An internal pilot phase in the main trial will
confirm the feasibility of recruiting and randomising suf-
ficient GP practices, PIPs, care homes and residents, the
availability of data for primary outcome at 3 months and
that there are no intervention-related safety concerns
prior to progression to the main trial. This has started
and will complete in mid late 2020.
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